A5072704683- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Nail Diseases and Treatments
- Fungal Infections and Studies
- Reproductive Physiology in Livestock
- Contact Dermatitis and Allergies
- Psoriasis: Treatment and Pathogenesis
- Mental Health Treatment and Access
- Genetic and phenotypic traits in livestock
- Autoimmune Bullous Skin Diseases
- Ruminant Nutrition and Digestive Physiology
- Plant Pathogens and Fungal Diseases
- CAR-T cell therapy research
- Suicide and Self-Harm Studies
- Infrared Thermography in Medicine
- Surgical site infection prevention
- Effects of Environmental Stressors on Livestock
- Infectious Diseases and Mycology
- Genetic and rare skin diseases.
- Thermal Regulation in Medicine
- Dermatologic Treatments and Research
- Acute Myeloid Leukemia Research
- Dermatological and Skeletal Disorders
- Lung Cancer Treatments and Mutations
Memorial Sloan Kettering Cancer Center
2001-2023
Washington University in St. Louis
2000-2022
Charité - Universitätsmedizin Berlin
2010
Peter MacCallum Cancer Centre
2010
The University of Texas MD Anderson Cancer Center
2010
Ligand Pharmaceuticals (United States)
2001
New York University
2001
University of Cincinnati
2001
City of Hope
2001
University of California, Los Angeles
2001
Cutaneous T-cell lymphomas (CTCL) are malignancies of T cells appearing as skin lesions and responsive to retinoid therapy. Safety efficacy a novel RXR-selective (rexinoid) bexarotene (Targretin, LGD1069; Ligand Pharmaceuticals Inc, San Diego, CA) was evaluated single-agent oral therapy administered once daily in an open-label study patients with refractory advanced-stage CTCL.Ninety-four biopsy-confirmed CTCL advanced stages (IIB-IVB) were enrolled at 26 centers. Fifty-six received initial...
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics denileukin diftitox (DAB 389 IL-2, Ontak [Ligand Phar-maceuticals Inc, San Diego, CA]) in patients with stage Ib IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. PATIENTS AND METHODS: Patients biopsy-proven CTCL that expressed CD25 on ≥ 20% lymphocytes were assigned one two dose levels (9 or 18 μg/kg/d) administered 5 consecutive days...
PURPOSE This phase III, placebo-controlled, randomized trial was designed to investigate efficacy and safety of two doses denileukin diftitox (DD; DAB(389)-interleukin-2 [IL-2]), a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in patients with stage IA CD25 assay-positive cutaneous T-cell lymphoma (CTCL), including the mycosis fungoides Sézary syndrome forms disease, who had received up three prior therapies. The primary end point overall response...
To detect early changes in the metabolic profile of pregnant ewes subject to acute feed restriction at 130 days gestation, and establish indicators risk for ovine pregnancy toxaemia (OPT) diagnostic purposes.Twenty Corriedale with known mating dates, carrying a single fetus, were used. Ewes maintained on meadow grasslands gestation randomly divided two groups 10 ewes. The control group had ad libitum access pasture. restricted subjected an maximum 144 hours (6 days), free water. From start...
The development of pityriasis rubra pilaris (PRP) in three patients with human immunodeficiency virus (HIV) infection is described. Two the had onset severe generalized cystic acne concomitant their PRP. PRP and conglobata should be added to group cutaneous disorders that can present a more virulent manner setting HIV infection. association response treatment are discussed.
In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25 low expression). Patients received 18 μg/kg/day for 5 consecutive days every 3 weeks up to eight courses. The primary endpoint, overall response rate, 30.6% (95% confidence interval: 16.3, 48.1),...
This open-label phase III trial, a companion to an earlier placebo-controlled evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding DD primary treatment the trial. Twenty (stages IA–III) received 18 μg/kg/day intravenously on days 1–5 21-day cycle, for ≤8 cycles. Efficacy was assessed monthly during first year then every 3 months. The overall response rate 40%, mostly partial responses. Nine (all baseline...
Abstract: Xeroderma pigmentosum is a group of rare autosomal recessive disorders with defective DNA repair that provide insight into the basic mechanism carcinogenesis. It best human model linking clinical abnormalities and neoplasla to carcinogen exposure. We describe patient xeroderma numerous basal cell carcinomas, squamous melanomas treated radiation therapy, Mohs micrographic surgery, dermabrasion, isotretinoin prophylaxis.
Abstract Background The American Society of Heating, Refrigeration, and Air-Conditioning Engineers (ASHRAE) recommends that hospital operating rooms (OR) are controlled for temperature humidity with established ranges but does allow exceedances surgeons surgical procedures. There is currently no clear consensus or thresholds out-of-range in relation to risk site infections (SSI). A study was performed at Memorial Sloan Kettering Cancer Center (MSKCC) further examine if deviations pose a...
Chronic lymphocytic leukemia ( CLL / SLL ) is the most common in western world and its cutaneous dissemination a very uncommon phenomenon. Lymphomatoid papulosis LyP CD30 + lymphoproliferative disorder characterized by chronic, recurrent self healing skin lesions. Up to 20% of patients with have coexistent lymphoma. While association between two entities has been reported, their coexistence never documented. We describe 74‐year‐old man known thrombocytopenia who presented 2 year history...
<sec> <title>BACKGROUND</title> Gatekeeper training teaches community members to identify individuals at-risk of suicide and assist them with help-seeking. A new online program (Recognise Respond; R&R) was created address the need for a specific Australian context, in consultation clinicians, researchers, people lived experience suicide. </sec> <title>OBJECTIVE</title> The primary objective examine short- medium-term impacts R&R gatekeeper on confidence support an individual...